Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

Core Viewpoint - Perspective Therapeutics, Inc. announced the acceptance of an abstract on updated interim results from its Phase 1/2a trial of [Pb]VMT-α-NET for neuroendocrine tumors, to be presented at the ASCO Gastrointestinal Cancers Symposium in January 2025 [1][2] Company Overview - Perspective Therapeutics is a radiopharmaceutical development company focused on advanced treatment applications for various cancers [5] - The company utilizes proprietary technology with the alpha-emitting isotope Pb to target cancer cells specifically, aiming to improve treatment efficacy and minimize toxicity through a "theranostic" approach [5][6] Clinical Trials and Presentations - The interim safety and efficacy data of [Pb]VMT-α-NET will be presented during the "Poster Session B" at the ASCO-GI symposium on January 24, 2025 [2] - A conference call will be held on January 24, 2025, to discuss the data presented, featuring the lead investigator and members of the management team [3] Research and Development - The company is conducting Phase 1/2a imaging and therapy trials for its melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs at leading academic institutions [6] - Perspective has developed a proprietary Pb generator to secure key isotopes for clinical trials and commercial operations [6]